Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soligenix, Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical issuer developing rare-disease therapeutics and public health vaccine candidates. Form 8-K reports disclose clinical and regulatory events for HyBryte in cutaneous T-cell lymphoma and SGX945 (dusquetide) in Behçet's Disease, including trial-result announcements, orphan drug designations and corporate progress updates.
Registration statements and material-event filings describe Soligenix's capital structure, including common stock, warrants, preferred stock and at-the-market or public offering activity. The filing record also covers Nasdaq continued-listing compliance, material agreements, governance matters, operating and financial results, risk factors and shareholder voting matters tied to its drug-development pipeline.
Soligenix, Inc. amends its Form S-1 to register 4,253 shares of common stock (the “Warrant Shares”) issuable upon exercise of previously issued warrants. The prospectus states the Offering Warrants were initially exercisable at $6.40 per share; warrants to purchase 1,876 shares were amended in September 2025 to an exercise price of $1.35 and extended to September 25, 2029. The company reports 10,306,079 shares outstanding as of March 24, 2026. Assuming full exercise of the Offering Warrants, outstanding shares would increase to 10,310,332. The prospectus estimates net proceeds to the company of approximately $17,746 assuming full exercise. No selling stockholders are listed and no additional securities are being registered in this Amendment.
Soligenix, Inc. amends its Form S-1 to update the registration for 408,640 shares of common stock issuable upon exercise of previously issued warrants (the "Warrant Shares"). The prospectus states the Offering Warrants were originally exercisable at $24.00 and certain warrants (to purchase 105,501 shares) were amended in September 2025 to an exercise price of $1.35 with exercise extended to September 25, 2029. The company reports 10,306,079 shares outstanding pre-offering and a pro forma post-exercise figure of 10,714,719, and estimates net proceeds of approximately $7,417,762 assuming full exercise. The filing incorporates the Company’s audited results for the year ended December 31, 2025 and notes cash of $7.9 million as of that date and $5.9 million as of March 24, 2026, with a disclosed near-term funding need into late 2026.
Soligenix, Inc. filed its annual report detailing progress across its late-stage biopharmaceutical pipeline in rare diseases and public health. The company reports a non‑affiliate common stock market value of $4,590,609 based on the June 30, 2025 Nasdaq closing price and 10,306,079 common shares outstanding on March 24, 2026. Key programs include HyBryte™ for cutaneous T‑cell lymphoma, SGX302 for psoriasis, and dusquetide‑based candidates SGX945 and SGX942 for inflammatory and oncology‑related indications. The report highlights multiple regulatory designations, active Phase 3 and Phase 2a studies, new manufacturing partnerships, and long‑term patent protection for synthetic hypericin and vaccine platforms.
SOLIGENIX, INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 4.99% equal to 529,731 shares of common stock as of 12/31/2025.
The filing states Armistice Capital is investment manager of the Master Fund, which is the direct holder, and that Armistice and Mr. Boyd exercise shared voting and dispositive power over the reported 529,731 shares. The Master Fund disclaims beneficial ownership due to the Investment Management Agreement.
Soligenix, Inc. filed a report highlighting a shareholder update letter from its CEO on pipeline progress, milestones, financing and cash runway. The company states it has sufficient capital to meet its goals through 2026 and continues to pursue strategic options, including partnerships and potential M&A.
Soligenix expects peak annual net sales of HyBryte™ in the U.S. to exceed $90 million, within a worldwide CTCL market estimated at more than $250 million annually. The worldwide psoriasis opportunity for SGX302 is estimated to exceed $1 billion annually, and SGX945 in Behçet's Disease about $200 million, supporting a total potential of roughly $2 billion in global annual sales.
The company reported approximately $10.5 million in cash as of the quarter ended September 30, 2025, plus about $500 thousand from New Jersey’s NOL sales program, and remains focused on completing the confirmatory Phase 3 HyBryte™ FLASH2 trial and advancing ex-U.S. partnership discussions.
Soligenix, Inc. is establishing an at-the-market stock offering of up to $3,450,000 of common stock under its existing shelf registration, using Rodman & Renshaw as sales agent. Shares may be sold from time to time on The Nasdaq Capital Market or other U.S. trading markets at market-related or negotiated prices, with Rodman earning up to 3.0% of the gross sales price as commission.
The company had 10,086,130 shares outstanding as of January 20, 2026, and provides an illustrative scenario of selling 2,500,000 shares at $1.38 per share, which would increase shares outstanding to 12,586,130. Net proceeds are intended to fund research and development, commercialization activities, and general corporate and working capital needs. Soligenix is a late-stage biopharmaceutical company focused on rare disease treatments, including its HyBryte photodynamic therapy program for cutaneous T‑cell lymphoma and several vaccine and biodefense candidates.
Soligenix, Inc. has entered into an at-the-market equity sales agreement with Rodman & Renshaw, LLC, allowing the company to sell shares of its common stock from time to time with an aggregate offering price of up to $3,450,000. Sales, if any, will be made through Rodman as sales agent on The Nasdaq Capital Market or other U.S. trading markets, at market-related or negotiated prices, as defined in Rule 415 under the Securities Act.
The company will control key parameters for each sales period, such as the number of shares sold, time window, daily volume limits, and any minimum price. Soligenix is not obligated to sell any shares, may suspend solicitations, and either party may terminate the agreement under specified conditions, with the program ending no later than December 15, 2026 unless ended earlier. Rodman will receive a commission of up to 3.0% of gross proceeds, and shares will be issued under Soligenix’s effective Form S-3 shelf registration statement and a related prospectus supplement.
Soligenix consulting chief medical officer Richard Straube reported an equity award in the form of stock options. On December 11, 2025, he received options to acquire 10,000 shares of Soligenix common stock at an exercise price of $1.63 per share, expiring on December 10, 2035.
According to the filing, the option vested immediately as to 25% of the shares, with the remaining 75% vesting in 12 installments (or nearly equal installments) on each three‑month anniversary of December 11, 2025. The filing shows 10,000 derivative securities beneficially owned directly following this transaction.
Soligenix, Inc. reported an insider equity award to its chief scientific officer. On December 11, 2025, the officer received a stock option covering 100,000 shares of Soligenix common stock at an exercise price of $1.63 per share.
The option expires on December 10, 2035. According to the disclosure, 25% of the option vested immediately on December 11, 2025, and the remaining 75% will vest in 12 approximately equal installments on each three-month anniversary of that date.
Soligenix, Inc. reported an insider equity award to its Chief Financial Officer, Jonathan L. Guarino. He received a stock option grant covering 100,000 options to purchase common stock at an exercise price of $ 1.63 per share on December 11, 2025.
The option expires on December 10, 2035. It vested immediately as to 25% of the shares, with the remaining 75% scheduled to vest in 12 equal installments on each three month anniversary of December 11, 2025. Following this grant, he beneficially owns 100,000 derivative securities directly.